IMG 007
Alternative Names: HMPL-A28; IMG-007Latest Information Update: 13 May 2024
At a glance
- Originator HUTCHMED
- Developer Inmagene
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action OX40 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Phase I/II Alopecia areata; Atopic dermatitis
Most Recent Events
- 07 May 2024 Inmagene completes enrolment in its phase I/II trial in Alopecia areata in USA, Canada (IV) (NCT06060977)
- 06 May 2024 Efficacy and adverse event data from a phase Ib/IIa trial in Atopic dermatitis released by Inmagene
- 26 Apr 2024 Inmagene Biopharmaceuticals terminates a phase I/II trial in Atopic dermatitis (Treatment-experienced) in Canada (IV) as the sponsor believes that results from Cohort 1 will provide reliable information for further development decision (NCT05984784)